C4 Therapeutics (CCCC) AI Stock Analysis

• Market Cap: $221.50M
• Dividend Yield: N/A
• Average Volume (3M): 2.73M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.45
• Revenue Growth: 16.55%
• EPS Growth: 16.73%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 93,065,820
• 10 Day Avg. Volume: 2,962,242
• 30 Day Avg. Volume: 2,726,464
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.23
• Enterprise Value/Revenue: -1.46
• Enterprise Value/Gross Profit: -1.65
• Enterprise Value/Ebitda: 0.45
• 1Y Price Target: $8.20
• Price Target Upside: 234.69% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 47 Neutral
• Price Target: $2.50 ▲(2.04% Upside)

C4 Therapeutics' stock score is primarily impacted by its financial performance, which is weighed down by persistent losses and cash flow challenges. Technical analysis shows mixed signals, with no strong momentum in either direction. The valuation is unattractive due to a negative P/E ratio and lack of dividends. These factors collectively result in a lower overall stock score.

Positive Factors

Proprietary Technology

C4 Therapeutics' proprietary protein degradation technology positions it as a leader in innovative cancer treatments, offering a competitive edge in the biopharmaceutical sector.

Revenue Growth

The company demonstrates strong revenue growth, indicating successful partnerships and increasing adoption of its technology, which supports long-term business expansion.

Strategic Partnerships

Strategic partnerships provide a stable revenue stream and validate the company's technology, enhancing its market position and potential for future growth.

Negative Factors

Profitability Challenges

Ongoing losses and negative cash flows highlight operational inefficiencies, posing a risk to financial stability and requiring strategic adjustments for sustainable growth.

Negative Cash Flow

Negative cash flows indicate challenges in cash generation, which can strain financial resources and limit the company's ability to invest in growth initiatives.

Margin Sustainability

Negative margins reflect cost management issues, impacting profitability and necessitating improvements to achieve financial health and competitive advantage.

C4 Therapeutics Business Overview & Revenue Model

Company Description

C4 Therapeutics (CCCC) is a biotechnology company focused on developing innovative therapeutics that harness the power of targeted protein degradation to treat cancer and other diseases. The company operates within the biopharmaceutical sector, leveraging its proprietary platform to create a pipeline of drug candidates designed to selectively degrade disease-causing proteins. C4 Therapeutics aims to address unmet medical needs by providing more effective and safer treatment options for patients with various types of cancer.

How the Company Makes Money

C4 Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies that seek to leverage its proprietary protein degradation technology. The company may receive upfront payments, milestone payments tied to the achievement of specific development goals, and royalties on sales of products developed through these collaborations. Additionally, C4 Therapeutics may engage in grant funding or government contracts to support research and development efforts. The success of its revenue model is heavily reliant on the advancement of its drug candidates through clinical trials and their eventual commercialization in partnership with established pharmaceutical companies.

C4 Therapeutics Financial Statement Overview

Summary

C4 Therapeutics faces significant financial challenges, with persistent losses impacting profitability and cash flows. While the balance sheet remains relatively stable, the company needs to address its operational inefficiencies to improve financial health. Strategic adjustments may be necessary to enhance revenue generation and cost management to achieve sustainable growth.

Income Statement

The income statement reveals a company struggling with profitability. The TTM (Trailing-Twelve-Months) shows negative EBIT and net income, indicating operational challenges. Although there's a modest revenue growth of 11.8% from the previous year, margins remain negative, suggesting ongoing difficulties in cost management or revenue generation.

Balance Sheet

The balance sheet shows a reasonable equity ratio of 61.07%, indicating a solid capital structure with more assets funded by equity. However, the debt-to-equity ratio of 0.33 reflects manageable leverage but could pose risks if financial performance does not improve. Return on equity remains negative due to ongoing losses.

Cash Flow

Cash flow analysis indicates issues with cash generation, as both operating and free cash flows are negative in the TTM (Trailing-Twelve-Months). The operating cash flow to net income ratio is negative, pointing to inefficiencies in converting sales into cash, while free cash flow is deteriorating, signaling cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	34.24M	35.58M	20.76M	31.10M	45.78M	33.20M
Gross Profit	30.42M	35.58M	13.02M	23.52M	42.88M	-45.24M
EBITDA	-112.50M	-103.37M	-122.10M	-124.28M	-78.84M	-62.89M
Net Income	-111.58M	-105.32M	-132.49M	-128.18M	-83.89M	-66.33M
Balance Sheet
Total Assets	296.53M	349.60M	376.45M	430.84M	506.76M	400.14M
Cash, Cash Equivalents and Short-Term Investments	214.55M	244.90M	253.68M	276.15M	309.28M	371.69M
Total Debt	62.92M	65.76M	70.98M	87.15M	42.88M	22.92M
Total Liabilities	122.46M	133.62M	130.34M	141.61M	117.16M	119.35M
Stockholders Equity	174.06M	215.99M	246.11M	289.23M	389.61M	280.79M
Cash Flow
Free Cash Flow	-87.58M	-65.34M	-108.55M	-111.44M	-88.24M	-67.90M
Operating Cash Flow	-87.41M	-65.16M	-106.84M	-105.94M	-86.97M	-67.25M
Investing Cash Flow	81.88M	-51.27M	158.35M	58.42M	-189.34M	-190.50M
Financing Cash Flow	10.57M	45.34M	45.49M	1.15M	171.40M	348.93M

C4 Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.45
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Positive. The current price of 2.45 is above the 20-day moving average (MA) of 2.29, below the 50-day MA of 2.55, and above the 200-day MA of 2.24, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 51.61 is Neutral, neither overbought nor oversold. The STOCH value of 45.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCCC.

C4 Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CCCC	47 Neutral	$221.50M	―	-52.99%	―	16.55%	16.73%
SLS	43 Neutral	$248.91M	―	-180.71%	―	―	64.43%
MCRB	42 Neutral	$156.27M	-2.25	―	―	-100.00%	66.57%
ELDN	35 Underperform	$208.39M	―	-16.20%	―	―	―
TVGN	33 Underperform	$138.01M	―	―	―	―	-406.67%

C4 Therapeutics Corporate Events

C4 Therapeutics Announces Stock and Warrants Offering

On October 16, 2025, C4 Therapeutics announced an underwritten offering of common stock and warrants, expected to close on October 17, 2025. The company anticipates net proceeds of approximately $117 million, extending its cash runway to the end of 2028, with potential total proceeds reaching $341.7 million if all warrants are exercised.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

C4 Therapeutics Presents Phase 1 Trial Data

On October 16, 2025, C4 Therapeutics announced the presentation of data from its Phase 1 clinical trial of cemsidomide combined with dexamethasone for relapsed/refractory multiple myeloma, highlighting its potential efficacy and safety profile. Additionally, the company terminated a sales agreement prospectus with TD Securities, impacting its stock sale strategy, while maintaining the agreement’s validity for future use, having previously raised approximately $9.6 million through stock sales.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

C4 Therapeutics Partners with Pfizer for Clinical Trial

On October 1, 2025, C4 Therapeutics announced a clinical trial collaboration and supply agreement with Pfizer. Under this agreement, Pfizer will provide elranatamab, a BCMAxCD3 bispecific antibody, at no cost for C4T’s upcoming Phase 1b trial. This trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab for treating relapsed/refractory multiple myeloma. The collaboration aims to establish an optimal dose for this combination therapy, potentially improving outcomes for multiple myeloma patients.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

C4 Therapeutics Reports Promising Phase 1 Trial Results

On September 20, 2025, C4 Therapeutics announced data from its Phase 1 clinical trial of cemsidomide, an IKZF1/3 degrader, in combination with dexamethasone for relapsed/refractory multiple myeloma. The trial showed promising results with a 50% overall response rate at the highest dose level and a differentiated safety profile, supporting further development for potential accelerated approval. The company plans to initiate Phase 2 and Phase 1b studies in 2026, aiming to position cemsidomide as a class-leading treatment option.

The most recent analyst rating on (CCCC) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

C4 Therapeutics Reports Q2 2025 Financial Results

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines through targeted protein degradation, primarily in the oncology sector. The company leverages its proprietary TORPEDO platform to advance its research and development efforts.

C4 Therapeutics Completes Phase 1 Trial Enrollment

On August 7, 2025, C4 Therapeutics announced the completion of enrollment and dose escalation for its Phase 1 trial of cemsidomide in multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL), showing promising response rates. The company plans to align with the FDA on a Phase 2 dose by the end of 2025 and initiate registrational development in early 2026, focusing on MM treatment. Financially, C4T reported a decrease in revenue for Q2 2025 compared to the previous year, primarily due to a previous milestone payment, but maintained a strong cash position expected to fund operations until mid-2027.

The most recent analyst rating on (CCCC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.